Q-omics provides the consensus-scored EIF5AL1 profile across patient tissues and cancer cell-line models. EIF5AL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, EIF5AL1 is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, EIF5AL1 RNA expression shows 10,329 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, STAD, and THYM as cancer lineages where EIF5AL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF5AL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF5AL1 survival associations across molecular data types. EIF5AL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF5AL1 RNA expression–survival associations across cancer types. High EIF5AL1 expression shows unfavorable associations in LUAD, but favorable associations in SCLC, CESC, UCEC, DLBC and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for EIF5AL1 RNA expression.
This table summarizes EIF5AL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF5AL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF5AL1 shows higher tumor expression in STAD, KIRP, CHOL, ESCA, UCEC and READ. The STAD box plot shows higher EIF5AL1 RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p = .001).
This table shows molecular features associated with EIF5AL1 in patient tissues and cancer cell lines. In patient samples, EIF5AL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF5AL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LIVER.
